Background {#Sec1}
==========

Many recent multicenter epidemiological studies have evaluated sepsis \[[@CR1]--[@CR7]\], although there is very little information regarding its epidemiology in Japan \[[@CR1], [@CR2]\]. Despite the limited amount of Japanese information, epidemiological data regarding severe sepsis are important for guiding clinical practice and the design of clinical studies. Therefore, the present study aimed to retrospectively evaluate a large population of patients with severe sepsis in intensive care units (ICUs) throughout Japan.

Methods {#Sec2}
=======

The present study analyzed the unlinkable anonymized database of the Japan Septic Disseminated Intravascular Coagulation (JSEPTIC DIC) study \[[@CR8]\]. Cases of shock, respiratory failure, or renal failure were defined as patients with a cardiovascular, respiratory, or renal Sequential Organ Failure Assessment (SOFA) score of ≥4 on day 1 \[[@CR9]\]. Cases of disseminated intravascular coagulation (DIC) were defined as patients with a Japanese Association for Acute Medicine DIC score of ≥4 on day 1. All data were expressed as number (percent), mean ± standard deviation, or median (interquartile range), as appropriate. Survival rates were evaluated using the Kaplan-Meier method. All analyses were performed using SPSS software (version 22; SPSS Inc., Chicago, IL).

Results {#Sec3}
=======

The present study included 3195 consecutive patients (2111 patients without shock and 1084 patients with shock). These patients included 1916 men (mean age 68 ± 14 years) and 1279 women (mean age 71 ± 15 years). The mean Acute Physiology and Chronic Health Evaluation II score among all patients was 23 ± 9. The primary infection sites are presented in Table [1](#Tab1){ref-type="table"}. The blood culture results and responsible microorganisms are presented in Table [2](#Tab2){ref-type="table"}. The frequencies of administering various adjunct treatments for severe sepsis during the first 7 days after ICU admission are shown in Table [3](#Tab3){ref-type="table"}. The survival curves for patients with and without various medical conditions are presented in Fig. [1](#Fig1){ref-type="fig"}. The estimated survival rates at 28 and 90 days among all patients with severe sepsis after the ICU admission were 73.6 and 56.3 %, respectively.Table 1Primary infection site responsible for the sepsisWithout shockWith shockTotal*n* = 2111*n* = 1084*n* = 3195Abdomen661 (31 %)371 (34 %)1032 (32 %)Lung/thorax575 (27 %)252 (23 %)827 (26 %)Urinary tract349 (17 %)160 (15 %)509 (16 %)Bone/soft tissue251 (12 %)123 (11 %)374 (12 %)Cardiovascular system54 (3 %)14 (1 %)68 (2 %)Central nervous system44 (2 %)19 (2 %)63 (2 %)Catheter-related23 (1 %)21 (2 %)44 (1 %)Other37 (2 %)23 (2 %)60 (2 %)Unknown117 (6 %)101 (9 %)218 (7 %)Data are expressed as number (percent)Table 2Microorganisms responsible for the sepsis and blood culture resultsWithout shockWith shockTotal*n* = 2111*n* = 1084*n* = 3195Microorganisms responsible for the sepsis Gram-negative rod774 (35%)421 (39%)1165 (37%) Gram-positive coccus477 (23%)261 (24%)738 (23%) Fungus43 (2%)14 (1%)57 (2%) Virus20 (1%)8 (1%)28 (1%) Mixed infection254 (12%)146 (14%)400 (13%) Other40 (2%)18 (2%)58 (2%) Unknown533 (25%)216 (20%)749 (23%)Blood culture Positive866 (41%)540 (50%)1406 (44%) Negative1,083 (51%)508 (47%)1591 (50%) Not taken162 (8%)36 (3%)198 (6%)Data are expressed as number (percent)Table 3Frequencies of various adjunct treatments for severe sepsis during the first 7 days after the ICU admissionAdjunct treatments DIC treatments1498 (47%)  Antithrombin990 (31%)  Thrombomodulin856 (27%)   Co-administration of antithrombin and thrombomodulin496 (16%)  Protease inhibitors392 (12%)  Heparinoids167 (5%) Immunoglobulin976 (31%) Low-dose steroids777 (24%) Renal replacement therapy890 (28%) Non-renal indication renal replacement therapy266 (8%) Polymyxin B-direct hemoperfusion692 (22%)Data are presented as number (percentage)*DIC* disseminated intravascular coagulation, *ICU* intensive care unitFig. 1Survival curves for patients with and without various medical conditions. The patients with medical conditions exhibited a poorer survival rate, compared to the patients without the conditions. Cases of shock, respiratory failure, or renal failure were defined as a cardiovascular, respiratory, or renal Sequential Organ Failure Assessment (SOFA) score of ≥4 on day 1. Cases of disseminated intravascular coagulation (DIC) were defined as a DIC score of ≥4 on day 1

Discussion {#Sec4}
==========

The present study evaluated the characteristics, treatments, and outcomes from 3195 patients with severe sepsis in 42 ICUs throughout Japan. The earlier epidemiological reports from after 2005 are summarized in the Additional file [1](#MOESM1){ref-type="media"}: Table S1. Although two previous Japanese studies have reported epidemiological information from 890 Japanese patients with severe sepsis, most of the participating institutions were university hospitals \[[@CR1], [@CR2]\]. In contrast, approximately half of the participating institutions in the present study were municipal hospitals. Furthermore, we included both general and emergency ICUs. Nevertheless, the distributions of age, severity, and mortality rates in the present study were similar to the findings from two previous Japanese studies \[[@CR1], [@CR2]\].

Patients with severe sepsis in other countries are generally younger than their Japanese counterparts \[[@CR1]--[@CR7]\]. Furthermore, other countries have higher mortality rates for patients with severe sepsis, compared to the rate from the present study, although the Acute Physiology and Chronic Health Evaluation II scores are similar for Japanese patients and other patients with sepsis \[[@CR1]--[@CR7]\]. However, the reports from the other countries evaluated patients with sepsis during an earlier period (2002--2010), compared to the patients from the three Japanese reports (2007--2013) \[[@CR1]--[@CR7]\]. Furthermore, mortality among patients with sepsis has decreased on an annual basis, and these factors may explain the different mortality rates in Japan and other countries.

The present study's mortality rates for severe sepsis with and without shock are similar to the results from previous Japanese studies \[[@CR1], [@CR2]\]. However, severe sepsis is frequently complicated by respiratory failure, renal failure, and DIC \[[@CR10]\], and the previous studies did not evaluate the mortality rates for severe sepsis in cases with respiratory or renal failure \[[@CR1], [@CR2]\]. Thus, the present study provides the first survival curve data for Japanese patients with severe sepsis according to their complications with shock, respiratory failure, renal failure, or DIC.
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DIC, disseminated intravascular coagulation; ICU, intensive care unit; JSEPTIC DIC, Japan Septic Disseminated Intravascular Coagulation; SOFA, Sequential Organ Failure Assessment
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